Scientists test Radiotherapy-Immunotherapy combo in fight against tough bladder cancers
NCT ID NCT02560636
Summary
This early-stage study is testing whether combining a type of immunotherapy drug (pembrolizumab) with a short, intense course of radiotherapy is safe and effective for people with advanced bladder cancer. It will involve about 34 patients whose cancer is either locally advanced or has spread. The main goal is to find the safest dose of the drug to use alongside the radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NIHR Biomedical Research Centre at RM and ICR (https://www.cancerbrc.org/)
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.